Stockreport

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatmen [Read more]